Stockscreener 앱 받기
1.23
3.36%
0.04
시간 외 거래:
1.21
-0.02
-1.63%
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190|Chg%:-0.030 - TradingKey
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Allarity Therapeutics Inc (ALLR) News, Articles, Events & Latest Updates - Stocktwits
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
Allarity Therapeutics (ALLR) Edges Higher as Stock Tests Narrow Trading RangeTRIN Signal - dars.gov.et
Allarity Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Biotech Focuses on Pipeline ExecutionEstimate Accuracy - dars.gov.et
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics (ALLR) Tests Support After 2.92% Decline – Key Levels Under ScrutinyMean Reversion Trade - dars.gov.et
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Allarity Therapeutics Obtains CLIA Certification For In-House DRP Testing And Advances Stenoparib Toward FDA Registration - marketscreener.com
Allarity Therapeutics obtains CLIA lab certification - Investing.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
Allarity Therapeutics obtains CLIA lab certification By Investing.com - Investing.com Nigeria
Allarity’s Denmark lab gets CLIA status for U.S. cancer-trial testing - Stock Titan
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Offset Investor ConcernsAnalyst Earnings Estimate - DonanımHaber
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year? - NewsBreak: Local News & Alerts
Allarity Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesSubscription Growth Report - dars.gov.et
Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com
Allarity receives U.S. patent for stenoparib diagnostic test By Investing.com - Investing.com Nigeria
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - Yahoo Finance
Price to earnings forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Price to book forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLR) - TradingView
ALLR Forecast — Price Target — Prediction for 2027 - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Allarity Therapeutics Inc (ALLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Progress in Advanced Ovarian Cancer at ESMO 2026 - Minichart
Form 8K Allarity Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allarity Therapeutics (NASDAQ: ALLR) showcases Phase 2 stenoparib ovarian cancer trial - Stock Titan
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - Investing News Network
Allarity to present trial poster at cancer congress - Investing.com
Allarity to present trial poster at cancer congress By Investing.com - Investing.com Canada
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Allarity Therapeutics Inc (ALLR) Institutional Confidence - TradingKey
Allarity Therapeutics Inc (ALLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics Q1 2026 Earnings: EPS Beat by 24.24% Amid Ongoing Clinical DevelopmentRetail Earnings Report - Bölüm Sonu Canavarı
1.97%
0.83%
자본화:
|
볼륨(24시간):